Shares of Cheniere Energy, Inc. (LNG) are higher by 2.01% to $55.23 in morning trading on Tuesday following Carl Icahn’s disclosure that he’s boosted his stake in the liquid natural gas company to 9.6 % from 8.2% in early August,.
Icahn disclosed Monday after the close of trading that he has bought 3.3 million shares of Cheniere since Wednesday. That gives him 22.7 million shares of the company’s stock.
—
SunEdison, Inc. (SUNE) is seeing a big move Tuesday, as the company’s shares have surged by over 5% on the day on news the company’s CEO has purchased 4,800 SUNE shares. The solar company also announced that it will begin construction on the company’s first community solar project in Massachusetts, a 2.7 megawatt (MW) DC solar farm in the town of Foxborough. SundEdison share were also resumed with a ‘Buy’ at Bank of America/Merrill (BAC) with $18 price target.
—
BlackRock, Inc. (BLK) shares gained 1.13% to $304.53 in early trading after the name was added to “Conviction Buy List” at Goldman Sachs (GS).
Blackrock shares are down 6.25% year-over-year and 14.19% year-to-date. In the past 52 weeks, shares of New York City-based investment manager have traded between a low of $275.00 and a high of $382.84.
BlackRock, Inc. has a current market cap of $50.68 billion.
—
Evoke Pharma Inc (EVOK) shares jumped 15 percent to $3.84 in early trading after the specialty pharmaceutical company announced that its Phase 3 clinical trial design for EVK-001 is consistent with the FDA’s draft guidance.
“We are pleased to see the recommendations contained in the FDA’s Draft Guidance on gastroparesis are consistent with the feedback we received from the FDA for our Phase 3 study of EVK-001, which gives us further confidence in the design of our ongoing study,” said in a statement Dave Gonyer, R.Ph., President and CEO of Evoke Pharma Inc.
—
XenoPort, Inc. (XNPT) shares are down 25% to $5.04 in the first couple of hours of trading despite the company reporting positive Phase 2 study results for XP23829 as a potential treatment for patients with psoriasis. Xenoport said the XP23829 Phase 2 study results were strong enough to justify moving the drug into a Phase 3 study next year.
XNPT shares jumped 19% to $8.00 in pre-market trading on Tuesday.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply